AAOpt: Presbyopia-correcting CSF-1 demonstrates consistent pupil restriction

News
Video

CSF-1 (0.4% pilocarpine HCl), a presbyopia-correcting drop candidate from Orasis, demonstrated consistent pupil restriction, which also suggests neuroadaptation in patients with presbyopia to the drop over time.

Jacob R. Lang, OD, FAAO, presented a poster at the 2023 American Academy of Optometry (AAOpt) meeting. The poster, entitled, "Persistence of Near Vision Improvement and Pupil Size: Results of the Pooled (NEAR) Phase 3 Studies of CSF-1 (0.4% pilocarpine HCl) for Presbyopia," details data on Orasis presbyopia-correcting drop candidate, which is expected to receive an FDA decision by the PDUFA date of October 22, 2023.

Video transcript

Editor's note: This transcript has been lightly edited for clarity.

Jacob R. Lang, OD, FAAO:
Hi, I'm Jacob Lang. I'm with Associated Eye Care in Stillwater, Minnesota and Hudson, Wisconsin. My poster is about CSF-1 and persistence of pupil change, as well as near adaptation that occurs with use of this presbyopia-correcting medication. In this research, we saw consistent pupil restriction, with pupils in the range of 2 to 3 millimeters at both one, eight, and 15 days. The percentage of 3 line responders improved from day 1 to day 8, and again from day 8 to 15.

Based on this improvement we saw over time, this may indicate nueroadaptation occurring in these presbiopic patients as they learn how this medication works and as their brains realize how to see better at near. I think this leads into further research and understanding how our brains really interact with our visual system especially, with near correction.

The future of presbyopia research is bright. I think there's a lot of demand [and] a lot of opportunity for improving our patients visions in this frustrating visual condition.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Mitch Ibach, OD, FAAO, details a presentation he gave with Tanner Ferguson, MD, at the Collaborative Care Symposium 2025.
Carolyn Majcher, OD, FAAO, details a Collaborative Care Symposium 2025 presentation given with Prethy Rao, MD.
Mitch Ibach, OD, FAAO, details the importance of identifying the best candidates and practicing comanagement for refractive surgery.
Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.
Mitch Ibach, OD, FAAO, details the importance to unveiling the underlying cause of dry eye in a CCS 2025 presentation.
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Steven Greenstein, MD, one of the cochairs of the Collaborative Care Symposium gave some insight into the upcoming conference and what attendees can expect.
Dr Julie Poteet reports on patient-reported outcomes using lipid-containing artificial tear
Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
Karl Stonecipher ASCRS 2025
© 2025 MJH Life Sciences

All rights reserved.